Open symposium in Sugiyama Laboratory  

Open symposium in Sugiyama Laboratory  

「Recent Development and Perspective of DMPK Research」 


To whom it may concern

 

   Please let us announce that we have started our research in the second term of Sugiyama Laboratory from Aprir 1.

   We have an opportunity that Dr. Ronald S Obach and Dr. Amit Kalgutkar (Pfizer) and Dr. Peter Bonate (Astellas) will visit our laboratory on June 16th.   

On this occasion we will hold the Open Symposium in Sugiyama Laboratory : Recent Development and Perspective of DMPK Research, 

inviting researchers from both domestic and international pharmaceutical companies who collaborate with Sugiyama laboratory. 

  We believe that it must be a valuable opportunity with you.

 

   Speaker including Dr. Sugiyama will give you a talk about the latest findings about recent development and perspective of DMPK research .

The symposium will be held in English, and registration fee is free.

Your attendance will be greatly appreciated.

              

Date:     June 16 (Tue)  12:30-17:45

Place:   RIKEN Yokohama Koryu-toh

RIKEN Yokohama URL < http://www.yokohama.riken.jp/access/index.html> 

Language:                        English

Registration Fee:              Free

Symposium Program:       Please kindly refer to the attached program for more details.

 

Registration:

Please fill in the following registration form and send it to us <info@riken-sugiyama.jp>, no later than 12:00, on June 9th (Tue.) .

 

------------------------------------------------

Registration Form

-       Name:           

-       Affiliation:      

-       E-mail:           

-       Tel:                

------------------------------------------------


≪Program≫  


12:30-13:10 (30+10)  Ronald S Obach  (Pfizer) 

Recent Challenges in Predicting Drug Metabolisam and How We Are Trying to Solve Them



13:10-13:50 (30+10)    Amit Kalgutkar (Pfizer) 

Toxicophores in Drug Design: Potential for "Trouble"? 

  


13:50-14:30 (30+10)    Peter Bonate (Astellas) 

“Compound selection based on PK/PD modeling in oncology” 

   


14:30-15:10 (30+10)    Yuichi Sugiyama (RIKEN) 

Prediction of complex DDI from in vitro data on metabolism and transport 

 


15:10-15:30    Break 

  


15:30-15:50 (15+5)   Sumito Ito and Satoshi Senda (Genomembrane) 

Joint Project with RIKEN Sugiyama’s Lab: Establishment of the transporter expression system for drug-induced tissue(hepatic and renal) injury prediction 

  


15:50-16:15 (15+10)  Yoshihisa Shitara (Meiji Seika Pharma) 

Kinetic analysis of time dependent inhibition of cyclosporin A for OATP1B1 mediated hepatic uptake of substrates 

  


16:15-16:40(15+10)   Saki Izumi and Yoshitane Nozaki (Eisai) 

Impact of substrate selection on in vitro OATP1B1 inhibition profiles for the prediction of DDIs 

  


16:40-17:05 (15+10)   Tomohisa Nakada (Mitsubishi Tanabe Pharma) 

Estimation of unbound intracellular–medium(plasma) concentration ratios (Kpuu) of 

Poorly-Metabolised Anionic Drugs Using Rat and Human Hepatocytes 


 

17:05- 17:30 (15+10)   Ryuta Asaumi (Ono Pharma)    

Establishment of rifampicin PBPK modeling which predicts all kinds of interactions including induction / inhibition of enzymes and transporters. 



17:30-17:45  Concluding remarks      Ronald S Obach,  Yuichi Sugiyama